Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Want to see RCUS full AI Analyst Report?
RCUS Stock Chart & Stats
$24.25
-$0.04(-0.26%)
At close: 4:00 PM EST
$24.25
-$0.04(-0.26%)
Day’s Range― - ―
52-Week Range$7.06 - $28.72
Previous CloseN/A
Volume107.84K
Average Volume (3M)1.06M
Market Cap
$3.15B
Enterprise Value$2.41B
Total Cash (Recent Filing)$981.00M
Total Debt (Recent Filing)$99.00M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
May 05, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding125,349,480
10 Day Avg. Volume672,844
30 Day Avg. Volume1,056,032
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)4.06
Price to Sales (P/S)10.36
P/FCF Ratio-5.29
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue9.74
Enterprise Value/Gross Profit9.95
Enterprise Value/Ebitda-7.64
Forecast
1Y Price Target
$35.56Price Target Upside46.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$92.28M
Bulls Say, Bears Say
Bulls Say
Dose Selection And Biomarker ValidationA specific daily casdatifan dose was validated by trial data and suppression of a serum biomarker correlated with clinical benefit, supporting the chosen regimen and enabling potential patient selection strategies.
Pivotal Trial Progress And Development RiskA multinational pivotal study pairing casdatifan with a commonly used kinase inhibitor is actively enrolling, which may reduce development risk if the trial completes enrollment and reads out as planned.
Single‑agent EfficacyCasdatifan monotherapy produced notably longer progression‑free survival and higher objective response rates than the only approved HIF‑2α therapy, suggesting strong single‑agent activity that could translate into clinical differentiation.
Bears Say
Competitive Pressure From Rival RegimensA competing HIF‑2α plus tyrosine kinase inhibitor regimen could present stronger Phase‑3 data and faster adoption, raising the efficacy benchmark and risking patient enrollment and commercial share for casdatifan.
Safety And Tolerability ConcernsCasdatifan data showed notable rates of anemia, hypoxia, cardiac dysfunction and treatment discontinuations in some cohorts, creating potential hurdles for clinical development and market uptake.
Small Early‑stage Dataset RiskEarly results come from a small patient group and may not be maintained in larger, more diverse randomized trials, so confirmatory data are needed to increase confidence in the efficacy signals.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $7.06 and its highest was $28.72 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Arcus Biosciences Inc’s market cap is $3.15B.
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is May 05, 2026 which is in 11 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Feb 25, 2026. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.106 by $0.216.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -0.88.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 125,349,480 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.106. Following the earnings report the stock price went down -3.601%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Currently, no hedge funds are holding shares in RCUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.56 (46.62% Upside)
$35.56 (46.62% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 334.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.74%
12-Months-Change
Fundamentals
Return on Equity
-65.77%
Trailing 12-Months
Asset Growth
36.00%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
RCUS Company Deck
RCUS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum for casdatifan — notably improved ORR (45% at 100 mg QD), durable PFS (median 15.1 months in the 100 mg cohort), low primary progression supporting a TKI‑sparing frontline strategy, an efficient ARC‑20 platform enabling rapid cohort expansion, a robust cash balance (~$1.0B) with runway into H2 2028, and near‑term clinic entry of immunology programs. Key risks discussed include an upcoming futility analysis (STAR‑121), a paused/dose‑reduced AstraZeneca volru combination with immune AE considerations, competition from Merck’s belzutifan program, and high ongoing R&D spend that depends on successful enrollment and readouts. On balance, the highlights (clinical differentiation, commercial opportunity, cash runway, and pipeline progress) strongly outweigh the manageable program and competitive risks.View all RCUS earnings summariesRCUS Stock 12 Month Forecast
Average Price Target
$35.56
▲(46.62% Upside)
Technical Analysis
Ownership Overview
4.38% Insiders
15.87% Mutual Funds
0.03% Other Institutional Investors
61.96% Public Companies and
Individual Investors